| LSVAX | VSCIX | LSVAX / VSCIX | |
| Total Expense Ratio | 1.40 | 0.03 | 4,667% |
| Annual Report Gross Expense Ratio | 1.46 | 0.03 | 4,867% |
| Fund Existence | 29 years | 29 years | - |
| Gain YTD | 20.254 | 14.591 | 139% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 5000000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 355M | 189B | 0% |
| Annual Yield % from dividends | 0.68 | 1.23 | 55% |
| Returns for 1 year | 4.08 | 22.58 | 18% |
| Returns for 3 years | -12.81 | 43.44 | -29% |
| Returns for 5 years | -31.42 | 35.13 | -89% |
| Returns for 10 years | -36.38 | 156.07 | -23% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GSPKX | 20.05 | 0.12 | +0.60% |
| Goldman Sachs US Eq Div and Prem Instl | |||
| GSIQX | 23.62 | N/A | N/A |
| Goldman Sachs GQG Ptnrs Intl Opps R | |||
| HSIIX | 29.59 | -0.08 | -0.27% |
| Carillon Eagle Small Cap Growth I | |||
| CCWSX | 21.56 | -0.16 | -0.74% |
| Baird Chautauqua International Gr Inv | |||
| RYCFX | 49.56 | -1.15 | -2.27% |
| Rydex Biotechnology C | |||